29 marzo 2018
Seattle Genétics Participará en la Antibodies & Antibody Drug Conjugates . 9 - 10 April 2018 . London,UK .
Es lo que tiene ir de la mano con el Lider Mundial en ADCs.
The results from PharmaMar show that in HER2-expressing tumors, MI130004 generates a longer lasting response and inhibits significantly tumor growth providing a higher median progression free survival time in comparison with Trastuzumab ...
Suscribirse a:
Comentarios (Atom)